{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"20.4","value":"7.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"The response rate (percentage) is the percent of patients whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 200 mg pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year (up to 18 cycles)","title":"Overall Confirmed Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}